Overview: Free PSA TestIntroduction: The Free PSA Test measures free PSA to diagnose prostate cancer, causing urinary issues. Following 2023 ASCO guidelines, it uses immunoassays for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in serology for patients with suspected prostate cancer.
Other Names: Free PSA Assay, Prostate-Specific Antigen Free Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: PSA testing began in the 1980s with prostate cancer research. Free PSA assays improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures free PSA to diagnose prostate cancer, guides treatment, and evaluates patients with urinary issues.
Test Parameters: 1. Free PSA Level
Pretest Condition: No fasting required. Collect serum or plasma. Report history of urinary issues or prostate symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document urinary issues, prostate enlargement, or family history of prostate cancer. Include current medications, especially 5-alpha-reductase inhibitors.
Consent: Written consent required, detailing the tests purpose, prostate cancer implications, and risks of sample collection.
Procedural Considerations: Uses immunoassays to measure free PSA levels. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for prostate cancer diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or recent prostate manipulation can affect results. Medications may lower PSA levels.
Clinical Significance: Low free PSA percentage suggests prostate cancer, guiding biopsy or imaging. High free PSA may indicate benign conditions.
Specialist Consultation: Consult a urologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Total PSA, prostate biopsy, or MRI to confirm prostate cancer diagnosis.
Test Limitations: Non-specific for prostate cancer; clinical correlation is needed. Sample quality affects sensitivity.
References: ASCO Prostate Cancer Guidelines, 2023; Journal of Urology, Catalona WJ, 2022.
